← All organizations
Highest phase reached
Phase 3
Timeline
2010s
- Jun 1, 2014
Kura Oncology, Inc.— Founded
2020s
- Nov 13, 2025
ziftomenib— Marketing Organization
Drugs by trial phase (27 distinct, 22 trials)
Phase 3 (5 own, 0 via acquisition)
Phase 2 (12 own, 0 via acquisition)
Phase 1 (10 own, 0 via acquisition)
Indications
Studied for
- Carcinoma
- Carcinoma, Squamous Cell
- Head and Neck Neoplasms
- Leukemia
- Leukemia, Myeloid, Acute
- Leukemia, Myelomonocytic, Chronic
- Leukemia, Myelomonocytic, Juvenile
- Lymphoma
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Peripheral
- Myelodysplastic Syndromes
- Neoplasms
- Preleukemia
- Squamous Cell Carcinoma of Head and Neck
- Syndrome
- Thyroid Neoplasms
Marketed drugs (1)
Recent trials (24)
- NCT05738538Lead sponsorN/A—
- NCT04809233Lead sponsorN/A—
- NCT06930352CollaboratorPhase 2Jan 10, 2026
- NCT07007312Lead sponsorPhase 3Sep 26, 2025
- NCT06655246Lead sponsorPhase 1Jan 31, 2025
- NCT06376162CollaboratorPhase 1Nov 30, 2024
- NCT06448013CollaboratorPhase 1Nov 29, 2024
- NCT06397027CollaboratorPhase 1Oct 31, 2024
- NCT06001788OfficialPhase 1Dec 31, 2023
- NCT06001788Lead sponsorPhase 1Dec 31, 2023
- NCT05848687CollaboratorPhase 1/Phase 2Nov 1, 2023
- NCT06026410Lead sponsorPhase 1Oct 18, 2023
- NCT05735184Lead sponsorPhase 1Jul 18, 2023
- NCT05693090Lead sponsorPhase 1Feb 1, 2023
- NCT04997902Lead sponsorPhase 1/Phase 2Nov 30, 2021
Details
- Founded
- La Jolla, CA, US Jun 1, 2014
- Last known activity
- Jan 10, 2026